The first patient has been enrolled in a Phase 2 clinical trial testing MRM-3379, Mirum Pharmaceuticals’ experimental oral treatment,…
Articles by Margarida Maia, PhD
Spinogenix’s experimental oral therapy SPG601 reduced abnormal high-frequency brain activity in men with fragile X syndrome and increased…
KER-0193, Kaerus Bioscience’s oral treatment candidate for fragile X syndrome, was safe and well tolerated, and showed predictable…
A Phase 2 clinical trial to test MRM-3379, an experimental oral treatment for fragile X syndrome, is expected…
With $1.6 million in pre-seed funding, researchers have launched a new biotech company called Aptadir Therapeutics that will develop RNA-based…
July is Fragile X Awareness Month, and this year, there are many ways to help build and spread knowledge about…
Researchers have developed a highly-sensitive test that can reliably detect trace activity levels of FMR1 — the faulty gene in…
University of Rochester researcher Lynne E. Maquat, PhD, is co-recipient of this year’s Gruber Genetics Prize for her discovery…
Girls and women with fragile X syndrome show different learning impairments relative to boys and men with the disease,…
Capsules containing very small doses (microdoses) of psilocybin are ready to be used in a future Nova Mentis clinical…